Long-Term Study Suggests Parkinson’s Drug Rasagiline May Slow Progression Of Movement Disorder

There is hope that the drug rasagiline can do what no other medication for Parkinson’s disease now does — slow the progression of a devastating degenerative brain disease that eventually robs people of their ability to move and function. Now a new study looking at the long-term effects of rasagiline (Azilect) on newly diagnosed patients indicates that people who began the drug earlier continued to do better than those for whom treatment was delayed six months.

More: continued here

Filed under: Clinical Trials on January 27th, 2009